A cocktail of antibodies against the coronavirus developed by the British-Swedish laboratory AstraZeneca led to a “67% reduction” in severe or fatal cases in phase 3 clinical trials, the pharmaceutical company announced in a statement.
Trials of the AZD7442 drug, consisting of a combination of antibodies, “resulted in a statistically satisfactory reduction” in “severe cases of covid-19 or deaths from the disease compared to a placebo in non-hospitalized patients with mild symptoms or moderate, “explained AstraZeneca, according to the news agency AFP.
Participants received the treatment within five days of the first symptoms, and preliminary analysis of the results shows that “AZD7442 reduced the risk of developing severe or fatal COVID-19 in 67% of cases compared with the placebo, “the statement said.
90% of the participants belonged to categories of patients considered at high risk of developing severe forms of Covid-19, including those with comorbidities.
“As severe COVID-19 cases continue around the world, there is a significant need for new therapies such as AZD7442 to protect vulnerable populations,” said Hugh Montgomery, professor of intensive care medicine at University College London and one of the principal investigators in this clinical trial, in which 903 people participated.
AstraZeneca will submit the data to health authorities and has already submitted an application to the US Food and Drug Administration, the FDA, for approval of the drug.